As winter arrives, the stark shift to dry air and central heating presents a challenge for those with eczema and psoriasis.

FOR Dar es Salaam resident Frank Latamani, the chronic skin condition known as Psoriasis has become not only a painful ordeal ...

Arcutis Biotherapeutics recently announced that the FDA has accepted its supplemental New Drug Application for ZORYVE cream 0.3% to treat plaque psoriasis in children aged 2 to 5 years, with a PDUFA ...

The company continues to receive good news from the Food and Drug Administration.

Itching can be caused by infections, allergies, and also by skin problems such as eczema, and sometimes psoriasis. It can also be a side effect of a surprising number of drugs, including those ...

The sNDA was supported by data from a 4 week MUSE study and a long-term open-label study in children aged 2 to 5 years.

Investing.com -- Arcutis Biotherapeutics Inc (NASDAQ:ARQT) stock rose 4.5% on Monday after the FDA accepted the company’s application to expand the use of its psoriasis treatment to younger children.

Biologic therapy use among patients with psoriatic disease was associated with a lower risk for malignancy compared with topical therapy use.

Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical ...

The Dry Skin Cream, Lotion, and Ointment Market is poised for robust expansion, with the global valuation expected to reach ...

Investigational ZORYVE cream 0.05% was formulated for the delicate skin of infants and young children with mild to moderate atopic ...

If you have thicker psoriasis plaques, you may benefit from using a cream that contains one of the following ingredients, which can lift up the plaque and make it softer: Dr. Katz notes that ...